Skip to content
2000
Volume 32, Issue 4
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

Mucosal Melanoma (MM) is an aggressive disease that is distinct from cutaneous melanoma in risk factors, prognosis, and treatment. Surgical treatment is currently the treatment of choice for localized disease; however, the recurrence rate is common. For advanced or metastatic disease, immunotherapy with PD-1 inhibitors and anti-CTLA is generally first-line treatment, however the overall responses to immunotherapy in MM are often lower and less robust when compared to that observed in cutaneous melanoma. Adoptive-TIL therapy has shown great promise. Other advances, particularly through the exploration of novel and combination therapies, are a step forward and a hope to improve outcomes in patients with mucosal melanoma. In this review, we summarize current treatment options for MM, and we updated future clinical trials available for this population of patients.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpd/10.2174/0113816128340751241220045149
2025-01-02
2026-02-18

  • From This Site

    /content/journals/cpd/10.2174/0113816128340751241220045149
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. ChangA.E. KarnellL.H. MenckH.R. The National Cancer Data Base report on cutaneous and noncutaneous melanoma.Cancer19988381664167810.1002/(SICI)1097‑0142(19981015)83:8<1664::AID‑CNCR23>3.0.CO;2‑G9781962
     [Google Scholar]
  2. McLaughlinCC WuX-C JemalA MartinHJ RocheLM ChenVW Incidence of noncutaneous melanomas in the U.S 2005.Cancer2005103510001007
     [Google Scholar]
  3. KukD. ShoushtariA.N. BarkerC.A. PanageasK.S. MunhozR.R. MomtazP. Prognosis of mucosal, uveal, acral, nonacral cutaneous, and unknown primary melanoma from the time of first metastasis.Oncologist201621848854
     [Google Scholar]
  4. LianB. CuiC.L. ZhouL. SongX. ZhangX.S. WuD. SiL. ChiZ.H. ShengX.N. MaoL.L. WangX. TangB.X. YanX.Q. KongY. DaiJ. LiS.M. BaiX. ZhengN. BalchC.M. GuoJ. The natural history and patterns of metastases from mucosal melanoma: An analysis of 706 prospectively-followed patients.Ann. Oncol.201728486887310.1093/annonc/mdw69428039178
     [Google Scholar]
  5. BoerF.L. HoV.K.Y. LouwmanM.W.J. SchraderA.M.R. ZuurC.L. BlankC.U. van PoelgeestM.I.E. KapiteijnE.H.W. Trends in incidence and survival of 1496 patients with mucosal melanoma in The Netherlands (1990–2019).Cancers2023155154110.3390/cancers1505154136900332
     [Google Scholar]
  6. ChiZ. LiS. ShengX. SiL. CuiC. HanM. GuoJ. Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: A study of 522 consecutive cases.BMC Cancer20111118510.1186/1471‑2407‑11‑8521349197
     [Google Scholar]
  7. SutherlandC.M. ChmielJ.S. HensonD.E. WinchesterD.P. Patient characteristics, methods of diagnosis, and treatment of mucous membrane melanoma in the United States of America.J. Am. Coll. Surg.199417955615667952459
     [Google Scholar]
  8. ChenS.W. LiM.H. LiuJ.L. ChenJ.T. WangJ. LiH. LiX.Y. ZhangY. SongM. LuJ.X. ChenW.K. Treatment outcomes of mucosal melanoma of the head and neck: Analysis of 190 cases from a single institution.Laryngoscope Investig. Otolaryngol.20238368669210.1002/lio2.107237342113
     [Google Scholar]
  9. Clavero-RoviraL. Gómez-TomásÁ. Bassas-FreixasP. BodetD. FerrerB. Hernández-LosaJ. Muñoz-CouseloE. Pérez-BenaventeA. García-PatosV. Ferrándiz-PulidoC. Mucosal melanoma clinical management and prognostic implications: A retrospective cohort study.Cancers202416122710.3390/cancers1601022738201654
     [Google Scholar]
  10. WolchokJ.D. Chiarion-SileniV. GonzalezR. GrobJ.J. RutkowskiP. LaoC.D. CoweyC.L. SchadendorfD. WagstaffJ. DummerR. FerrucciP.F. SmylieM. ButlerM.O. HillA. Márquez-RodasI. HaanenJ.B.A.G. GuidoboniM. MaioM. SchöffskiP. CarlinoM.S. LebbéC. McArthurG. AsciertoP.A. DanielsG.A. LongG.V. BasT. RitchingsC. LarkinJ. HodiF.S. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma.J. Clin. Oncol.202240212713710.1200/JCO.21.0222934818112
     [Google Scholar]
  11. KnightA. KarapetyanL. KirkwoodJ.M. Immunotherapy in Melanoma.Cancers 2023154110610.3390/cancers1504110636831449
     [Google Scholar]
  12. BedikianA.Y. MillwardM. PehambergerH. ConryR. GoreM. TrefzerU. PavlickA.C. DeContiR. HershE.M. HerseyP. KirkwoodJ.M. HaluskaF.G. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.J. Clin. Oncol.200624294738474510.1200/JCO.2006.06.048316966688
     [Google Scholar]
  13. TyrrellH. PayneM. Combatting mucosal melanoma: Recent advances and future perspectives.Melanoma Manag.201853MMT1110.2217/mmt‑2018‑000330459941
     [Google Scholar]
  14. CarvajalR.D. SpencerS.A. LydiattW. Mucosal melanoma: A clinically and biologically unique disease entity.J. Natl. Compr. Canc. Netw.201210334535610.6004/jnccn.2012.003422393195
     [Google Scholar]
  15. ManolidisS. DonaldP.J. Malignant mucosal melanoma of the head and neck.Cancer19978081373138610.1002/(SICI)1097‑0142(19971015)80:8<1373::AID‑CNCR3>3.0.CO;2‑G9338460
     [Google Scholar]
  16. LeeS.P. ShimizuK.T. TranL.M. JuillardG. CalcaterraT.C. Mucosal melanoma of the head and neck: The impact of local control on survival.Laryngoscope1994104212112610.1288/00005537‑199402000‑000018302112
     [Google Scholar]
  17. NilssonP.J. Ragnarsson-OldingB.K. Importance of clear resection margins in anorectal malignant melanoma.Br. J. Surg.20109719810310.1002/bjs.678420013935
     [Google Scholar]
  18. MeletiM. LeemansC.R. de BreeR. VescoviP. SesennaE. van der WaalI. Head and neck mucosal melanoma: Experience with 42 patients, with emphasis on the role of postoperative radiotherapy.Head Neck200830121543155110.1002/hed.2090118704960
     [Google Scholar]
  19. PatelS.G. PrasadM.L. EscrigM. SinghB. ShahaA.R. KrausD.H. BoyleJ.O. HuvosA.G. BusamK. ShahJ.P. Primary mucosal malignant melanoma of the head and neck.Head Neck200224324725710.1002/hed.1001911891956
     [Google Scholar]
  20. BacharG. LohK.S. O’SullivanB. GoldsteinD. WoodS. BrownD. IrishJ. Mucosal melanomas of the head and neck: Experience of the Princess Margaret Hospital.200830101325133110.1002/hed.2087818704964
     [Google Scholar]
  21. HiekenT.J. KaneJ.M. WongS.L. Role of completion lymph node dissection for sentinel lymph node-positive melanoma20192610281034
     [Google Scholar]
  22. BromanK.K. HughesT. DossettL. SunJ. KirichenkoD. CarrM.J. SharmaA. BartlettE.K. NijhuisA.A.G. ThompsonJ.F. HiekenT.J. KottschadeL. DownsJ. GyorkiD.E. StahlieE. van AkkooiA. OllilaD.W. FrankJ. SongY. KarakousisG. MoncrieffM. NobesJ. VettoJ. HanD. FarmaJ.M. DeneveJ.L. FlemingM.D. PerezM.C. LoweM.C. Olofsson BaggeR. MattssonJ. LeeA.Y. BermanR.S. ChaiH. KroonH.M. TerasJ. TerasR.M. FarrowN.E. BeasleyG. HuiJ.Y.C. BeenL. KruijffS. KimY. NaqviS.M.H. SarnaikA.A. SondakV.K. ZagerJ.S. Active surveillance of patients who have sentinel node positive melanoma: an international, multi-institution evaluation of adoption and early outcomes after the multicenter selective lymphadenectomy trial II (MSLT-2).Cancer2021127132251226110.1002/cncr.3348333826754
     [Google Scholar]
  23. LianB. LiZ. WuN. LiM. ChenX. ZhengH. GaoM. WangD. ShengX. TianH. SiL. ChiZ. WangX. LaiY. SunT. ZhangQ. KongY. LongG.V. GuoJ. CuiC. Phase II clinical trial of neoadjuvant anti-PD-1 (toripalimab) combined with axitinib in resectable mucosal melanoma.Ann. Oncol.202435221122010.1016/j.annonc.2023.10.79337956739
     [Google Scholar]
  24. HoJ. MatteiJ. TetzlaffM. WilliamsM.D. DaviesM.A. DiabA. OlivaI.C.G. McQuadeJ. PatelS.P. TawbiH. WongM.K. FisherS.B. HannaE. KeungE.Z. RossM. WeiserR. SuS.Y. FrumovitzM. MeyerL.A. JazaeriA. PettawayC.A. GuadagnoloB.A. BishopA.J. MitraD. FarooqiA. BassettR. FariaS. NagarajanP. AmariaR.N. Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma.Front. Oncol.202212100115010.3389/fonc.2022.100115036324592
     [Google Scholar]
  25. LianB. SiL. CuiC. ChiZ. ShengX. MaoL. LiS. KongY. TangB. GuoJ. Phase II randomized trial comparing high-dose IFN-α2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma.Clin. Cancer Res.201319164488449810.1158/1078‑0432.CCR‑13‑073923833309
     [Google Scholar]
  26. LianB. SiL. ChiZ.H. ShengX.N. KongY. WangX. TianH. LiK. MaoL.L. BaiX. TangB.X. YanX.Q. LiS.M. ZhouL. DaiJ. TangX.W. RanF.W. YaoS. GuoJ. CuiC.L. Toripalimab (anti-PD-1) versus high- dose interferon-α2b as adjuvant therapy in resected mucosal melanoma: A phase II randomized trial.Ann. Oncol.202233101061107010.1016/j.annonc.2022.07.00235842199
     [Google Scholar]
  27. KottschadeL.A. PondG.R. OlszanskiA.J. ZakhariaY. Domingo-MusibayE. HaukeR.J. CurtiB.D. SchoberS. MilhemM.M. BlockM.S. HiekenT. McWilliamsR.R. SALVO.Clin. Cancer Res.202329122220222510.1158/1078‑0432.CCR‑22‑320737000165
     [Google Scholar]
  28. LianB. TianH. SiL. ChiZ. ShengX. WangX. Temozolomide plus cisplatin versus toripalimab (anti-PD-1) as adjuvant therapy in resected mucosal melanoma.20234195089508
     [Google Scholar]
  29. PostowM.A. HamidO. CarvajalR.D. Mucosal melanoma: Pathogenesis, clinical behavior, and management.Curr. Oncol. Rep.201214544144810.1007/s11912‑012‑0244‑x22661391
     [Google Scholar]
  30. NenclaresP. Ap DafyddD. BagwanI. BeggD. KerawalaC. KingE. LingleyK. PaleriV. PatersonG. PayneM. SilvaP. StevenN. TurnbullN. YipK. HarringtonK.J. Head and neck mucosal melanoma: The United Kingdom national guidelines.Eur. J. Cancer2020138111810.1016/j.ejca.2020.07.01732829104
     [Google Scholar]
  31. Locoregional mucosal melanoma: Epidemiology, clinical diagnosis, and treatment. 2024. Available from: https://www.uptodate.com/contents/locoregional-mucosal-melanoma-epidemiology-clinical-diagnosis-and-treatment?topicRef=138441&source=see_link#H32364415
  32. KrengliM MasiniL KaandersJHAM MaingonP OeiSB ZouhairA Radiotherapy in the treatment of mucosal melanoma of the upper aerodigestive tract: Analysis of 74 cases. A rare cancer network study.Int J Radiat Oncol Biol Phys.2006653751759
     [Google Scholar]
  33. JacquesS.K. McKeownJ. GroverP. JohnsonD.B. ZarembaA. DimitriouF. WeiserR. FaridM. NamikawaK. SullivanR.J. RutkowskiP. LebbeC. HamidO. ZagerJ.S. MichielinO. NeynsB. NakamuraY. RobertC. MehnertJ. AsciertoP.A. BhaveP. ParkB. ZimmerL. ManganaJ. MooradianM. PlaczkeJ. AllayousC. Glitza OlivaI.C. MehmiI. DepaloD. WickyA. SchwarzeJ.K. RoyS. BoatwrightC. VanellaV. LongG.V. MenziesA.M. LoS.N. CarlinoM.S. Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy.Eur. J. Cancer202419911356310.1016/j.ejca.2024.11356338278007
     [Google Scholar]
  34. DubusM. CharlesJ. LecciaM.T. MouretS. TrabelsiS. Long-term response of vulvar mucosal melanoma treated with neoadjuvant nivolumab.JAAD Case Rep.202338141610.1016/j.jdcr.2023.05.03737600735
     [Google Scholar]
  35. PostowM.A. LukeJ.J. BluthM.J. RamaiyaN. PanageasK.S. LawrenceD.P. IbrahimN. FlahertyK.T. SullivanR.J. OttP.A. CallahanM.K. HardingJ.J. D’AngeloS.P. DicksonM.A. SchwartzG.K. ChapmanP.B. GnjaticS. WolchokJ.D. HodiF.S. CarvajalR.D. Ipilimumab for patients with advanced mucosal melanoma.Oncologist201318672673210.1634/theoncologist.2012‑046423716015
     [Google Scholar]
  36. AlexanderM. MellorJ.D. McArthurG. KeeD. Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma.Med. J. Aust.20142011495310.5694/mja13.1044824999899
     [Google Scholar]
  37. ZimmerL. EigentlerT.K. KieckerF. SimonJ. UtikalJ. MohrP. BerkingC. KämpgenE. DippelE. StadlerR. HauschildA. FluckM. TerheydenP. RompelR. LoquaiC. AssiZ. GarbeC. SchadendorfD. Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma.J. Transl. Med.201513135110.1186/s12967‑015‑0716‑526541511
     [Google Scholar]
  38. Del VecchioM. Di GuardoL. AsciertoP.A. GrimaldiA.M. SileniV.C. PigozzoJ. FerraresiV. NuzzoC. RinaldiG. TestoriA. FerrucciP.F. MarchettiP. De GalitiisF. QueiroloP. TornariE. MarconciniR. CalabròL. MaioM. Efficacy and safety of ipilimumab 3 mg/kg in patients with pretreated, metastatic, mucosal melanoma.Eur. J. Cancer201450112112710.1016/j.ejca.2013.09.00724100024
     [Google Scholar]
  39. ShoushtariA.N. MunhozR.R. KukD. OttP.A. JohnsonD.B. TsaiK.K. RapisuwonS. ErogluZ. SullivanR.J. LukeJ.J. GangadharT.C. SalamaA.K.S. ClarkV. BuriasC. PuzanovI. AtkinsM.B. AlgaziA.P. RibasA. WolchokJ.D. PostowM.A. The efficacy of anti-PD-1 agents in acral and mucosal melanoma.Cancer2016122213354336210.1002/cncr.3025927533633
     [Google Scholar]
  40. SchaeferT. SatzgerI. GutzmerR. Clinics, prognosis and new therapeutic options in patients with mucosal melanoma.Medicine2017961e575310.1097/MD.000000000000575328072717
     [Google Scholar]
  41. TakahashiA. TsutsumidaA. NamikawaK. NakamuraY. MutoI. YamazakiN. The efficacy of nivolumab for unresectable metastatic mucosal melanoma.Ann Oncol201627vi383
     [Google Scholar]
  42. HamidO. RobertC. RibasA. HodiF.S. WalpoleE. DaudA. AranceA.S. BrownE. HoellerC. MortierL. SchachterJ. LongJ. EbbinghausS. IbrahimN. ButlerM. Antitumour activity of pembrolizumab in advanced mucosal melanoma: A post-hoc analysis of KEYNOTE-001, 002, 006.Br. J. Cancer2018119667067410.1038/s41416‑018‑0207‑630202085
     [Google Scholar]
  43. Moya-PlanaA. Herrera GómezR.G. RossoniC. DercleL. AmmariS. GiraultI. RoyS. ScoazecJ.Y. VagnerS. JanotF. EggermontA.M.M. RobertC. Evaluation of the efficacy of immunotherapy for non-resectable mucosal melanoma.Cancer Immunol. Immunother.20196871171117810.1007/s00262‑019‑02351‑731172258
     [Google Scholar]
  44. D’AngeloS.P. LarkinJ. SosmanJ.A. LebbéC. BradyB. NeynsB. SchmidtH. HasselJ.C. HodiF.S. LoriganP. SavageK.J. MillerW.H.Jr MohrP. Marquez-RodasI. CharlesJ. KaatzM. SznolM. WeberJ.S. ShoushtariA.N. RuisiM. JiangJ. WolchokJ.D. Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: A pooled analysis.J. Clin. Oncol.201735222623510.1200/JCO.2016.67.925828056206
     [Google Scholar]
  45. ShoushtariA.N. WagstaffJ. AsciertoP.A. ButlerM.O. LaoC.D. Marquez-RodasI. CheckMate 067: Long-term outcomes in patients with mucosal melanoma.2020381001910019
     [Google Scholar]
  46. DaviesH. BignellG.R. CoxC. StephensP. EdkinsS. CleggS. TeagueJ. WoffendinH. GarnettM.J. BottomleyW. DavisN. DicksE. EwingR. FloydY. GrayK. HallS. HawesR. HughesJ. KosmidouV. MenziesA. MouldC. ParkerA. StevensC. WattS. HooperS. WilsonR. JayatilakeH. GustersonB.A. CooperC. ShipleyJ. HargraveD. Pritchard-JonesK. MaitlandN. Chenevix-TrenchG. RigginsG.J. BignerD.D. PalmieriG. CossuA. FlanaganA. NicholsonA. HoJ.W.C. LeungS.Y. YuenS.T. WeberB.L. SeiglerH.F. DarrowT.L. PatersonH. MaraisR. MarshallC.J. WoosterR. StrattonM.R. FutrealP.A. Mutations of the BRAF gene in human cancer.Nature2002417689294995410.1038/nature0076612068308
     [Google Scholar]
  47. CurtinJ.A. BusamK. PinkelD. BastianB.C. Somatic activation of KIT in distinct subtypes of melanoma.J. Clin. Oncol.200624264340434610.1200/JCO.2006.06.298416908931
     [Google Scholar]
  48. BeadlingC. Jacobson-DunlopE. HodiF.S. LeC. WarrickA. PattersonJ. TownA. HarlowA. CruzF.III AzarS. RubinB.P. MullerS. WestR. HeinrichM.C. CorlessC.L. KIT gene mutations and copy number in melanoma subtypes.Clin. Cancer Res.200814216821682810.1158/1078‑0432.CCR‑08‑057518980976
     [Google Scholar]
  49. BaiX. MaoL.L. ChiZ.H. ShengX.N. CuiC.L. KongY. DaiJ. WangX. LiS.M. TangB.X. LianB. ZhouL. YanX.Q. GuoJ. SiL. BRAF inhibitors: Efficacious and tolerable in BRAF-mutant acral and mucosal melanoma.Neoplasma201764462663210.4149/neo_2017_41928485171
     [Google Scholar]
  50. BuchbinderE.I. WeiratherJ.L. ManosM. QuattrochiB.J. ShollL.M. BrennickR.C. BowlingP. BaileyN. MagaraceL. OttP.A. HaqR. IzarB. Giobbie-HurderA. HodiF.S. Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade.Cancer Med.20211082627263510.1002/cam4.378933724703
     [Google Scholar]
  51. SatzgerI. SchaeferT. KuettlerU. BroeckerV. VoelkerB. OstertagH. KappA. GutzmerR. Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas.Br. J. Cancer200899122065206910.1038/sj.bjc.660479119018266
     [Google Scholar]
  52. SteebT. WesselyA. PetzoldA. KohlC. ErdmannM. BerkingC. HepptM.V. c-Kit inhibitors for unresectable or metastatic mucosal, acral or chronically sun-damaged melanoma: A systematic review and one-arm meta-analysis.Eur. J. Cancer202115734835710.1016/j.ejca.2021.08.01534562816
     [Google Scholar]
  53. IqbalN. IqbalN. Imatinib: A breakthrough of targeted therapy in cancer.Chemother. Res. Pract.201420141910.1155/2014/35702724963404
     [Google Scholar]
  54. MengD. CarvajalR.D. KIT as an oncogenic driver in melanoma: An update on clinical development.Am. J. Clin. Dermatol.201920331532310.1007/s40257‑018‑0414‑130707374
     [Google Scholar]
  55. WoodmanS.E. TrentJ.C. Stemke-HaleK. LazarA.J. PriclS. PavanG.M. FermegliaM. GopalY.N.V. YangD. PodoloffD.A. IvanD. KimK.B. PapadopoulosN. HwuP. MillsG.B. DaviesM.A. Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates.Mol. Cancer Ther.2009882079208510.1158/1535‑7163.MCT‑09‑045919671763
     [Google Scholar]
  56. KimK.B. SanguinoA.M. HodgesC. PapadopoulosN.E. EtonO. CamachoL.H. BroemelingL.D. JohnsonM.M. BalloM.T. RossM.I. GershenwaldJ.E. LeeJ.E. MansfieldP.F. PrietoV.G. BedikianA.Y. Biochemotherapy in patients with metastatic anorectal mucosal melanoma.Cancer200410071478148310.1002/cncr.2011315042682
     [Google Scholar]
  57. BartellH.L. BedikianA.Y. PapadopoulosN.E. DettT.K. BalloM.T. MyersJ.N. HwuP. KimK.B. Biochemotherapy in patients with advanced head and neck mucosal melanoma.Head Neck200830121592159810.1002/hed.2091018798304
     [Google Scholar]
  58. LiS. WuX. YanX. ZhouL. ChiZ. SiL. CuiC. TangB. MaoL. LianB. WangX. BaiX. DaiJ. KongY. TangX. FengH. YaoS. FlahertyK.T. GuoJ. ShengX. Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis.J. Immunother. Cancer2022102e00403610.1136/jitc‑2021‑00403635193932
     [Google Scholar]
  59. ShibueT. WeinbergR.A. EMT, CSCs, and drug resistance: The mechanistic link and clinical implications.Nat. Rev. Clin. Oncol.2017141061162910.1038/nrclinonc.2017.4428397828
     [Google Scholar]
  60. EaswaranH. TsaiH.C. BaylinS.B. Cancer epigenetics: Tumor heterogeneity, plasticity of stem-like states, and drug resistance.Mol. Cell201454571672710.1016/j.molcel.2014.05.01524905005
     [Google Scholar]
  61. BurrellR.A. McGranahanN. BartekJ. SwantonC. The causes and consequences of genetic heterogeneity in cancer evolution.Nature2013501746733834510.1038/nature1262524048066
     [Google Scholar]
  62. TelekesA. HorváthA. Role of cell-free DNA in cancer treatment decision making2022146115
     [Google Scholar]
  63. RadvanyiL.G. BernatchezC. ZhangM. FoxP.S. MillerP. ChaconJ. WuR. LizeeG. MahoneyS. AlvaradoG. GlassM. JohnsonV.E. McMannisJ.D. ShpallE. PrietoV. PapadopoulosN. KimK. HomsiJ. BedikianA. HwuW.J. PatelS. RossM.I. LeeJ.E. GershenwaldJ.E. LucciA. RoyalR. CormierJ.N. DaviesM.A. MansarayR. FulbrightO.J. TothC. RamachandranR. WardellS. GonzalezA. HwuP. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients.Clin. Cancer Res.201218246758677010.1158/1078‑0432.CCR‑12‑117723032743
     [Google Scholar]
  64. BesserM.J. Shapira-FrommerR. ItzhakiO. TrevesA.J. ZippelD.B. LevyD. KubiA. ShoshaniN. ZikichD. OhayonY. OhayonD. ShalmonB. MarkelG. YerushalmiR. ApterS. Ben-NunA. Ben-AmiE. ShimoniA. NaglerA. SchachterJ. Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: Intent-to-treat analysis and efficacy after failure to prior immunotherapies.Clin. Cancer Res.201319174792480010.1158/1078‑0432.CCR‑13‑038023690483
     [Google Scholar]
  65. AndersenR. DoniaM. EllebaekE. BorchT.H. KongstedP. IversenT.Z. HölmichL.R. HendelH.W. MetÖ. AndersenM.H. thor StratenP. SvaneI.M. Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL2 regimen.Clin. Cancer Res.201622153734374510.1158/1078‑0432.CCR‑15‑187927006492
     [Google Scholar]
  66. GrigoleitG-U. KlugerH. ThomasS. ChesneyJ.A. Domingo-MusibayE. SanmamedM.F. 1086MO Lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with advanced mucosal melanoma after progression on immune checkpoint inhibitors (ICI): Results from the phase II C-144-01 study.Ann Oncol202334suppl2S654
     [Google Scholar]
  67. ForgetM.A. HaymakerC. HessK.R. MengY.J. CreasyC. KarpinetsT. FulbrightO.J. RoszikJ. WoodmanS.E. KimY.U. Sakellariou-ThompsonD. BhattaA. WahlA. FloresE. ThorsenS.T. TaveraR.J. RamachandranR. GonzalezA.M. TothC.L. WardellS. MansarayR. PatelV. CarpioD.J. VaughnC. FarinasC.M. VelasquezP.G. HwuW.J. PatelS.P. DaviesM.A. DiabA. GlitzaI.C. TawbiH. WongM.K. CainS. RossM.I. LeeJ.E. GershenwaldJ.E. LucciA. RoyalR. CormierJ.N. WargoJ.A. RadvanyiL.G. Torres-CabalaC.A. BeroukhimR. HwuP. AmariaR.N. BernatchezC. Prospective analysis of adoptive TIL therapy in patients with metastatic melanoma: response, impact of anti-CTLA-4, and biomarkers to predict clinical outcome.Clin. Cancer Res.201824184416442810.1158/1078‑0432.CCR‑17‑364929848573
     [Google Scholar]
  68. Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma.2024Available from: https://clinicaltrials.gov/study/NCT05545969?cond=Mucosal%20Melanoma&limit=100&aggFilters=status:act%20rec%20not&rank=1
  69. Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD-1 Immunotherapy in Patients With Resectable Head and Neck Mucosal Melanoma.2024Available from: https://clinicaltrials.gov/study/NCT03313206?cond=Mucosal%20Melanoma&limit=100&aggFilters=status:act%20rec%20not&rank=7&page=1
  70. Single Arm Study of Induction Chemoradiotherapy Combined With Surgery in the Treatment of Locally Advanced SNMM.2024Available from: https://clinicaltrials.gov/study/NCT05009446?cond=Mucosal%20Melanoma&limit=100&aggFilters=status:act%20rec%20not&rank=10&page=1
  71. Postoperative Adjuvant Treatment of Completely Resected Mucosal Melanoma Phase II Study. 2024Available from: https://clinicaltrials.gov/study/NCT04462965?cond=Mucosal%20Melanoma&limit=100&aggFilters=status:act%20rec%20not&rank=4&page=1
  72. Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery. 2024Available from: https://clinicaltrials.gov/study/NCT05111574?cond=Mucosal%20Melanoma&limit=100&aggFilters=status:act%20rec%20not&rank=13&page=1
  73. Toripalimab Combined With Radiotherapy and Chemotherapy in the Treatment of SNMM After Endoscopic Surgery. 2024Available from: https://clinicaltrials.gov/study/NCT04879654?cond=Mucosal%20Melanoma&limit=100&aggFilters=status:act%20rec%20not&rank=20&page=1
  74. Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Acral and Mucosal Melanoma Patients Progressed From Prior Immune Check Point Inhibitor.2024Available from: https://clinicaltrials.gov/study/NCT05436990?cond=Mucosal%20 Melanoma&limit=100&aggFilters=status:act%20rec%20not& rank=9&page=1
  75. Definition of vactosertib - NCI Drug Dictionary. 2011Available from: https://www.cancer.gov/publications/dictionaries/cancer- drug/def/vactosertib
  76. CowardJ. AbedA. NagrialA. MarkmanB. Phase I open-label, dose escalation of YH003, an anti-CD40 monoclonal antibody in combination with toripalimab (anti-PD-1 mAb) in patients with advanced solid tumors.JCO202139suppl152580
     [Google Scholar]
  77. Envafolimab Combined With Recombinant Human Endostatin and First-line Chemotherapy Treat of Advanced Mucosal Melanoma. 2024Available from: https://clinicaltrials.gov/study/NCT06041724?cond=Mucosal%20Melanoma&limit=100&aggFilters=status:act%20rec%20not&rank=11&page=1
  78. Méndez-ValdésG. Gómez-HeviaF. Lillo-MoyaJ. González-FernándezT. AbelliJ. Cereceda-CornejoA. BragatoM.C. SasoL. RodrigoR. Endostatin and cancer therapy: A novel potential alternative to anti-VEGF monoclonal antibodies.Biomedicines202311371810.3390/biomedicines1103071836979697
     [Google Scholar]
  79. Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma.2024Available from: https://clinicaltrials.gov/study/NCT05089370?cond=Mucosal%20Melanoma&limit=100&aggFilters=status:act%20rec%20 not&rank=14&page=1
  80. Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma. 2024. Available from: https://clinicaltrials.gov/study/NCT04318717?cond=Mucosal%20Melanoma&limit=100&aggFilters=status:act%20rec%20not&rank=19&page=1
  81. Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6.2024Available from: https://clinicaltrials.gov/study/NCT04830124?cond=Mucosal%20Melanoma&limit=100&aggFilters=status:act%20rec%20not&rank=8&page=1
  82. VaishampayanU.N. TomczakP. MuzaffarJ. WinerI.S. RosenS.D. HoimesC.J. Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors: ARTISTRY-1.20224025002500
     [Google Scholar]
/content/journals/cpd/10.2174/0113816128340751241220045149
Loading
Mucosal Melanoma: An Overview of Recent Therapies
Curr. Pharm. Des. 32, 267 (2026); https://doi.org/10.2174/0113816128340751241220045149
/content/journals/cpd/10.2174/0113816128340751241220045149
/content/journals/cpd/10.2174/0113816128340751241220045149
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): cutaneous melanoma; immunotherapy; lymph node biopsy, radiation therapy; Mucosal melanoma; PD-1 inhibitors

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test